In AD, it has been shown that by using nano-based drug delivery, it has been possible to decrease Aβ production, aggregation, and clearance, as well as tau phosphorylation and packaging [75], in which significant progress has been demonstrated [76]. This evidence concerns the gene MAPT and Alzheimer disease.